Emerging Therapies for Pruritus

Pruritus, or chronic itch, remains one of the most distressing and quality-of-life impairing symptoms in dermatology. Over the past decade, understanding of the neuroimmune mechanisms driving itch has advanced dramatically, leading to the emergence of biologics and small molecules that target its molecular pathways. This review summarizes current and investigational therapies for atopic dermatitis (AD), psoriasis, and chronic spontaneous urticaria (CSU)—3 major pruritic dermatoses—while addressing real-world challenges in dermatologic practice. 

The Pathophysiology of Itch 

Chronic itch arises from complex crosstalk among immune cells, keratinocytes, and sensory neurons. In AD, Th2 cytokines, such as IL-4, IL-13, and IL-31, amplify both inflammation and neuronal sensitization, creating a self-perpetuating itch-scratch cycle.1 IL-31, in particular, is now recognized as a major pruritogenic cytokine.2 In psoriasis, IL-23/IL-17-mediated inflammation and neuropeptides such as substance P contribute significantly to pruritus.3,4 In CSU, mast-cell activation and IgE- or autoantibody-mediated degranulation trigger histamine and cytokine release, producing intense itch.5 

These mechanistic insights have reframed itch as an active neuroimmune process rather than a secondary symptom, guiding more targeted therapies. 

Atopic Dermatitis: Biologics and JAK Inhibitors Transform Itch Control 

FDA-Approved Therapies 

Dupilumab (anti-IL-4Rα) revolutionized moderate-to-severe AD therapy by blocking IL-4/IL-13 signaling and producing durable itch relief.1 Tralokinumab, approved in 2021, selectively inhibits IL-13 to reduce inflammation and pruritus.2 Lebrikizumab, approved in 2024, provides comparable efficacy with less frequent dosing.2 

Oral Janus kinase (JAK) inhibitors, including abrocitinib, upadacitinib, and baricitinib, achieve rapid itch reduction by inhibiting JAK-STAT-mediated cytokine signaling downstream of IL-4, IL-13, and IL-31.6 

Emerging Agents 

Investigational biologics, such as nemolizumab (anti-IL-31Rα), tezepelumab (anti-TSLP), and amlitelimab (anti-OX40L), have demonstrated robust antipruritic activity in phase II–III studies.7 IL-31 blockade offers a novel option for patients with persistent itch despite lesion clearance. 

Clinical Challenges 

Despite progress, residual itch remains common. Assessment tools such as the Numerical Rating Scale (NRS) and ItchyQoL lack objectivity and standardization.3 Clinicians must also manage long-term safety considerations with JAK inhibitors, including infection and thromboembolic risk.6 

Psoriasis: Recognizing and Targeting the Hidden Itch 

Although once regarded as “non-itchy,” psoriasis causes moderate-to-severe pruritus in most patients, correlating strongly with disease burden and mental-health impairment.3 

Current Therapies 

Biologics targeting TNF-α, IL-17, and IL-23, such as ixekizumab and ustekinumab, reduce itch along with plaque clearance, although itch endpoints remain secondary outcomes in trials.3 

Emerging Research 

Future therapies may focus directly on IL-31 and JAK-STAT pathways to treat residual itch, especially in “clear-skin, persistent-itch” phenotypes. Device-based modalities, including phototherapy, transcutaneous electrical nerve stimulation, and cold-plasma therapy, are being evaluated as adjunctive itch interventions.4 

Clinical Barriers 

Residual itch in clinically clear patients remains an unmet need. Dermatologists should document itch severity using validated measures to justify biologic selection and payer approval.3 

Chronic Spontaneous Urticaria: Beyond Antihistamines 

FDA-Approved and Emerging Options 

In 2025, the US Food and Drug Administration (FDA) approved dupilumab for CSU in patients ≥ age 12 years inadequately controlled by H1-antihistamines—the first new targeted biologic for urticaria in over a decade.5 Clinical trials showed marked improvement in itch severity and urticaria activity scores.5 

Omalizumab remains a mainstay, while Bruton's tyrosine kinase inhibitors such as remibrutinib and mast-cell-signaling modulators are emerging as next-generation antipruritic options.5,8 

Clinical Challenges 

Because itch dominates CSU symptomatology, dermatologists should include itch-specific outcomes in disease assessment. Barriers, such as cost, insurance authorization, and limited biologic access, remain substantial.5 

Quantifying Itch: Toward Objective Measurement 

Objective itch quantification remains elusive. Tools like the NRS, ItchyQoL, and Sleep Scratch Index are widely used yet inconsistent across studies.3 Innovations, such as wearable motion sensors and artificial intelligence-based scratch detection, may provide reproducible, objective endpoints for future trials.3 

The Neuroimmune Interface and Future Directions 

Emerging research underscores the epithelial-neuronal-immune axis as central to chronic pruritus, with IL-31, oncostatin M, transient receptor potential channels, and JAK-STAT signaling at the core.1,7 Personalized, biomarker-driven therapy guided by IL-31 levels, eosinophil counts, or nerve-fiber density represents the next frontier. 

Device-based adjuncts, such as phototherapy and neuromodulation, and behavioral approaches, such as habit reversal and mindfulness, continue to evolve as part of comprehensive itch management.4 

Conclusion 

Pruritus remains one of the most persistent and burdensome symptoms in dermatology. With modern biologics and small-molecule inhibitors, clinicians can now target the molecular and neural pathways underlying itch rather than its downstream manifestations. Ongoing innovations in IL-31 antagonism, JAK inhibition, and neuroimmune modulation promise durable, measurable relief for patients with chronic pruritic disorders. 

References 

  1. Labib A, Ju T, Yosipovitch G. Emerging treatments for itch in atopic dermatitis: a review. J Am Acad Dermatol. 2023;89(2):338-344. doi:10.1016/j.jaad.2023.04.057 
  2. Hernández-Zárate LA, Gómez-Núñez CA, Narváez-Labuhn S, Morales-Velázquez G, González-Uribe V. The evolving therapeutic landscape in atopic dermatitis. Explor Asthma Allergy. 2025;3:100966. doi:10.37349/eaa.2025.100966 
  3. Butler DC, Berger T, Elmariah S, et al. Chronic pruritus: a review. JAMA. 2024;331(24):2114-2124. doi:10.1001/jama.2024.4899 
  4. Zhu J, Zhao X, Navarini AA, Müller SM. Device-based physical therapies in chronic pruritus: a narrative review. J Am Acad Dermatol. 2024;91(4):699-705. doi:10.1016/j.jaad.2024.06.045 
  5. Li H, Arthur A, Forouzandeh M, Pomputius A, Cuervo-Pardo L, Montanez-Wiscovich M. New and emerging pharmacotherapies for pruritus: a systematic review and network meta-analysis. Dermatitis. 2025;36(4):333-342. doi:10.1089/derm.2023.0419 
  6. Drucker AM, Walwyn C, Chu C, et al. Living network meta-analysis to compare nemolizumab against other available targeted systemic treatments for atopic dermatitis. Br J Dermatol. 2025;193(3):548-552. doi:10.1093/bjd/ljaf166 
  7. Lo Y, Cheng TT, Huang CJ, Cheng YC, Chyuan IT. Advancing therapeutic strategies in atopic dermatitis: emerging targets and personalized approaches. Biomolecules. 2025;15(6):838. doi:10.3390/biom15060838 
  8. Licata G, Arisi M, Giorgio CM, et al. Emerging therapies in the treatment of prurigo nodularis: biological therapy and systematic review of literature. Dermatol Ther (Heidelb). 2025;15(7):1705-1718. doi:10.1007/s13555-025-01437-8 
Back to top